Vitamin D and COVID-19: where are we now?

dc.contributor.authorContreras-Bolivar, Victoria
dc.contributor.authorGarcia-Fontana, Beatriz
dc.contributor.authorGarcia-Fontana, Cristina
dc.contributor.authorMunoz-Torres, Manuel
dc.contributor.authoraffiliation[Contreras-Bolivar, Victoria] Univ Hosp Clin San Cecilio, Endocrinol & Nutr Unit, Granada, Spain
dc.contributor.authoraffiliation[Garcia-Fontana, Beatriz] Univ Hosp Clin San Cecilio, Endocrinol & Nutr Unit, Granada, Spain
dc.contributor.authoraffiliation[Garcia-Fontana, Cristina] Univ Hosp Clin San Cecilio, Endocrinol & Nutr Unit, Granada, Spain
dc.contributor.authoraffiliation[Munoz-Torres, Manuel] Univ Hosp Clin San Cecilio, Endocrinol & Nutr Unit, Granada, Spain
dc.contributor.authoraffiliation[Contreras-Bolivar, Victoria] Inst Invest Biosanitaria Granada Ibs Granada, Granada, Spain
dc.contributor.authoraffiliation[Garcia-Fontana, Beatriz] Inst Invest Biosanitaria Granada Ibs Granada, Granada, Spain
dc.contributor.authoraffiliation[Garcia-Fontana, Cristina] Inst Invest Biosanitaria Granada Ibs Granada, Granada, Spain
dc.contributor.authoraffiliation[Munoz-Torres, Manuel] Inst Invest Biosanitaria Granada Ibs Granada, Granada, Spain
dc.contributor.authoraffiliation[Garcia-Fontana, Beatriz] Inst Salud Carlos III, CIBERFES, Madrid, Spain
dc.contributor.authoraffiliation[Garcia-Fontana, Cristina] Inst Salud Carlos III, CIBERFES, Madrid, Spain
dc.contributor.authoraffiliation[Munoz-Torres, Manuel] Inst Salud Carlos III, CIBERFES, Madrid, Spain
dc.contributor.authoraffiliation[Munoz-Torres, Manuel] Univ Granada, Dept Med, Granada, Spain
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderEuropean Regional Development Fund (FEDER)
dc.contributor.funderJunta de Andalucia
dc.date.accessioned2025-01-07T14:03:35Z
dc.date.available2025-01-07T14:03:35Z
dc.date.issued2021-12-25
dc.description.abstractThe pandemic caused by the SARS-CoV-2 virus has triggered great interest in the search for the pathophysiological mechanisms of COVID-19 and its associated hyperinflammatory state. The presence of prognostic factors such as diabetes, cardiovascular disease, hypertension, obesity, and age influence the expression of the disease's clinical severity. Other elements, such as 25-hydroxyvitamin D (25(OH)D3) concentrations, are currently being studied. Various studies, mostly observational, have sought to demonstrate whether there is truly a relationship between 25(OH)D3 levels and the acquisition and/or severity of the disease. The objective of this study was to carry out a review of the current data that associate vitamin D status with the acquisition, evolution, and/or severity of infection by the SARS-CoV-2 virus and to assess whether prevention through vitamin D supplementation can prevent infection and/or improve the evolution once acquired. Vitamin D system has an immunomodulatory function and plays a significant role in various bacterial and viral infections. The immune function of vitamin D is explained in part by the presence of its receptor (VDR) and its activating enzyme 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) in immune cells. The vitamin D, VDR, and Retinoid X Receptor complex allows the transcription of genes with antimicrobial activities, such as cathelicidins and defensins. COVID-19 characteristically presents a marked hyperimmune state, with the release of proinflammatory cytokines such as IL-6, TNF-alpha, and IL-1 beta. Thus, there are biological factors linking vitamin D to the cytokine storm, which can herald some of the most severe consequences of COVID-19, such as acute respiratory distress syndrome. Hypovitaminosis D is widespread worldwide, so the prevention of COVID-19 through vitamin D supplementation is being considered as a possible therapeutic strategy easy to implement. However, more-quality studies and well-designed randomized clinical trials are needed to address this relevant question.
dc.identifier.doi10.1080/00325481.2021.2017647
dc.identifier.essn1941-9260
dc.identifier.issn0032-5481
dc.identifier.pmid34886758
dc.identifier.unpaywallURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787834
dc.identifier.urihttps://hdl.handle.net/10668/26101
dc.identifier.wosID734796400001
dc.issue.number3
dc.journal.titlePostgraduate medicine
dc.journal.titleabbreviationPostgrad. med.
dc.language.isoen
dc.organizationSAS - Hospital Universitario San Cecilio
dc.organizationSAS - Hospital Universitario San Cecilio
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.page.number195-207
dc.publisherTaylor & francis ltd
dc.rights.accessRightsopen access
dc.subjectVitamin D
dc.subject25-hydroxyvitamin D
dc.subjectvitamin D receptor (VDR)
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectRenin-angiotensin system
dc.subjectD-binding protein
dc.subjectD-receptor
dc.subjectD supplementation
dc.subjectD deficiency
dc.subjectTherapeutic implications
dc.subjectOxidative stress
dc.subjectMetabolism
dc.subjectResponses
dc.subjectDisease
dc.titleVitamin D and COVID-19: where are we now?
dc.typereview
dc.type.hasVersionVoR
dc.volume.number135
dc.wostypeReview

Files